Skip to main content
SpringerLink
Log in

Treatment of Neuroendocrine Cancer Metastatic to the Liver: The Role of Ablative Techniques

  • Review
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Carcinoid tumors and islet cell neoplasms are neuroendocrine neoplasms with indolent patterns of growth and association with bizarre hormone syndromes. These tumors behave in a relatively protracted and predictable manner, which allows for multiple therapeutic options. Even in the presence of hepatic metastases, the standard of treatment for neuroendocrine malignancy is surgery, either with curative intent or for tumor cytoreduction, i.e., resection of 90% or more of the tumor volume. Image-guided ablation, as either an adjunct to surgery or a primary treatment modality, can be used to treat neuroendocrine cancer metastatic to the liver. Image-guided ablative techniques, including radiofrequency ablation, alcohol injection, and cryoablation, can be used in selected patients to debulk hepatic tumors and improve patient symptoms. Although long-term follow-up data are not available, the surgical literature indicates that significant ablative debulking may improve patient survival. In this review, we discuss metastatic neuroendocrine disease and its treatment options, especially image-guided ablative techniques.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Moertel CG (1987) Karnofsky memorial lecture: An odyssey in the land of small tumors. J Clin Oncol 5:1502–1522

    PubMed  Google Scholar 

  2. Modlin IM, Sandor A (1997) An analysis of 8305 cases of carcinoid tumors. Cancer 79:813–829

    Article  CAS  PubMed  Google Scholar 

  3. Ihse I, Persson B, Tibblin S (1995) Neuroendocrine metastases of the liver. World J Surg 19:76–82

    Article  CAS  PubMed  Google Scholar 

  4. Proye C (2001) Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: Place for chemoembolization. World J Surg 25:685–688

    Article  CAS  PubMed  Google Scholar 

  5. Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229:815–821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH (1961) Life history of the carcinoid tumor of the small intestine. Cancer 14:901–912

    Article  CAS  PubMed  Google Scholar 

  7. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G (1995) Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425:547–560

    Article  CAS  PubMed  Google Scholar 

  8. Carty SE, Jensen RT, Norton JA (1992) Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 112:1024–1031

    CAS  PubMed  Google Scholar 

  9. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA (1998) Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg 187:88–92

    Article  CAS  PubMed  Google Scholar 

  10. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH (2000) Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 190:432–445

    Article  CAS  PubMed  Google Scholar 

  11. Grazi GL, Cescon M, Pierangeli F, Ercolani G, Gardini A, Cavallari A, Mazziotti A (2000) Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 47:481–486

    CAS  PubMed  Google Scholar 

  12. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169:36–42

    Article  CAS  PubMed  Google Scholar 

  13. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37

    Article  PubMed  Google Scholar 

  14. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y (1996) Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 20:908–914

    Article  CAS  PubMed  Google Scholar 

  15. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108:1091–1096

    CAS  PubMed  Google Scholar 

  16. Lehnert T (1998) Liver transplantation for metastatic neuroendocrine carcinoma: An analysis of 103 patients. Transplantation 66:1307–1312

    Article  CAS  PubMed  Google Scholar 

  17. Knechtle SJ, Kalayoglu M, D’Alessandro AM, Rikkers LF (1997) Proceed with caution: Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 225:345–346

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y, Blumgart LH (1999) Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10:397–403

    Article  CAS  PubMed  Google Scholar 

  19. Clouse ME, Perry L, Stuart K, Stokes KR (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55 [Suppl 3]:92–97

    PubMed  Google Scholar 

  20. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83:2293–2301

    Article  CAS  PubMed  Google Scholar 

  21. Moertel CG, Johnson CM, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, Rubin J, Kunselman S (1994) The management of patients with advanced carcinoma tumors and islet cell carcinomas. Ann Intern Med 120:302–309

    Article  CAS  PubMed  Google Scholar 

  22. Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K (1994) [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 131:577–581

    Article  CAS  PubMed  Google Scholar 

  23. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50:5969–5977

    CAS  PubMed  Google Scholar 

  24. Oberg K (2001) Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12 [Suppl 2]:S111–S114

    Article  PubMed  Google Scholar 

  25. Oberg K (1999) Neuroendocrine gastrointestinal tumors: A condensed overview of diagnosis and treatment. Ann Oncol 10 [Suppl 2]:S3–S8

    Article  PubMed  Google Scholar 

  26. Rivera E, Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21:36–38

    Article  CAS  PubMed  Google Scholar 

  27. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523

    Article  CAS  PubMed  Google Scholar 

  28. Eriksson B, Oberg K (1993) An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32:203–208

    Article  CAS  PubMed  Google Scholar 

  29. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E (2002) Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13:614–621

    Article  CAS  PubMed  Google Scholar 

  30. Berber E, Flesher N, Siperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26:985–990

    Article  PubMed  Google Scholar 

  31. Oberg K, Norheim I, Lind E, Alm G, Lundqvist G, Wide L, Jonsdottir B, Magnusson A, Wilander E (1986) Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treat Rep 70:1297–1304

    CAS  PubMed  Google Scholar 

  32. Moertel CG, Rubin J, Kvols LK (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7:865–868

    CAS  PubMed  Google Scholar 

  33. Jacobsen MB, Hanssen LE, Kolmannskog F, Schrumpf E, Vatn MH, Bergan A (1995) Interferon-alpha 2b, with or without prior hepatic artery embolization: Clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol 30:789–796

    Article  CAS  PubMed  Google Scholar 

  34. Oberg K (2000) State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 44:3–12

    CAS  PubMed  Google Scholar 

  35. Biesma B, Willemse PH, Mulder NH, Verschueren RC, Kema IP, de Bruijn HW, Postmus PE, Sleijfer DT, de Vries EG (1992) Recombinant interferon alpha-2b in patients with metastatic apudomas: Effect on tumours and tumour markers. Br J Cancer 66:850–855

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bowles BJ, Machi J, Limm WM, Severino R, Oishi AJ, Furumoto NL, Wong LL, Oishi RH (2001) Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg 136:864–869

    Article  CAS  PubMed  Google Scholar 

  37. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg 230:1–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Dodd GD III, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, Gillams AR, Karahan OI, Rhim H (2000) Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics 20:9–27

    Article  PubMed  Google Scholar 

  39. Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer: Initial experience in 24 patients. Radiology 220:145–149

    Article  CAS  PubMed  Google Scholar 

  40. Parikh AA, Curley SA, Fornage BD, Ellis LM (2002) Radiofrequency ablation of hepatic metastases. Semin Oncol 29:168–182

    Article  PubMed  Google Scholar 

  41. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ (2000) Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications. Ann Surg Oncol 7:593–600

    Article  CAS  PubMed  Google Scholar 

  42. Solbiati L, Livragh T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: Long-term results in 117 patients. Radiology 221:159–166

    Article  CAS  PubMed  Google Scholar 

  43. de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A (2000) Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 175:1619–1625

    Article  PubMed  Google Scholar 

  44. Solbiati L, Ierace T, Tonolini M, Osti V, Cova L (2001) Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 13:149–158

    Article  CAS  PubMed  Google Scholar 

  45. Cioni D, Lencioni R, Bartolozzi C (2001) Percutaneous ablation of liver malignancies: Imaging evaluation of treatment response. Eur J Ultrasound 13:73–93

    Article  CAS  PubMed  Google Scholar 

  46. Henn AR, Levine EA, McNulty W, Zagoria RJ (2003) Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol 181:1005–1010

    Article  PubMed  Google Scholar 

  47. Wessels FJ, Schell SR (2001) Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 95:8–12

    Article  CAS  PubMed  Google Scholar 

  48. Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A (2002) Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26:1052–1056

    Article  PubMed  Google Scholar 

  49. Giovannini M, Seitz JF (1994) Ultrasound-guided percutaneous alcohol injection of small liver metastases: Results in 40 patients. Cancer 73:294–297

    Article  CAS  PubMed  Google Scholar 

  50. Livraghi T, Vettori C, Lazzaroni S (1991) Liver metastases: Results of percutaneous ethanol injection in 14 patients. Radiology 179:709–712

    Article  CAS  PubMed  Google Scholar 

  51. Giovannini M (2002) Percutaneous alcohol ablation for liver metastasis. Semin Oncol 29:192–195

    Article  PubMed  Google Scholar 

  52. Seifert JK, Cozzi PJ, Morris DL (1998) Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14:175–183

    Article  CAS  PubMed  Google Scholar 

  53. Cozzi PJ, Englund R, Morris DL (1995) Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 76:501–509

    Article  CAS  PubMed  Google Scholar 

  54. Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP (1997) Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 122:1040–1047

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    T.D. Atwell, J.W. Charboneau, B.D. Lewis, M.R. Callstrom & M.A. Farrell

  2. Division of Gastroenterologic and General Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    F.G. Que & D.M. Nagorney

  3. Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    J. Rubin, H.C. Pitot & T.J. Hobday

Authors
  1. T.D. Atwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.W. Charboneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F.G. Que
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B.D. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D.M. Nagorney
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M.R. Callstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M.A. Farrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H.C. Pitot
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T.J. Hobday
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T.D. Atwell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atwell, T., Charboneau, J., Que, F. et al. Treatment of Neuroendocrine Cancer Metastatic to the Liver: The Role of Ablative Techniques. Cardiovasc Intervent Radiol 28, 409–421 (2005). https://doi.org/10.1007/s00270-004-4082-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-004-4082-6

Keywords

Search

Navigation